-
Something wrong with this record ?
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
P. Moreau, MA. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Špička, R. Baker, K. Kim, G. Martinez, CK. Min, L. Pour, X. Leleu, A. Oriol, Y. Koh, K. Suzuki, ML. Risse, G. Asset, S. Macé, T. Martin, IKEMA study group
Language English Country Great Britain
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
NLK
ProQuest Central
from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest)
from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest)
from 1992-01-04 to 3 months ago
Family Health Database (ProQuest)
from 1992-01-04 to 3 months ago
Psychology Database (ProQuest)
from 1992-01-04 to 3 months ago
Health Management Database (ProQuest)
from 1992-01-04 to 3 months ago
Public Health Database (ProQuest)
from 1992-01-04 to 3 months ago
- MeSH
- Anti-Inflammatory Agents therapeutic use MeSH
- Dexamethasone therapeutic use MeSH
- Progression-Free Survival MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Immunologic Factors therapeutic use MeSH
- Administration, Intravenous MeSH
- Drug Therapy, Combination MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiple Myeloma drug therapy MeSH
- Oligopeptides therapeutic use MeSH
- Prospective Studies MeSH
- Recurrence MeSH
- Aged MeSH
- Thalidomide analogs & derivatives therapeutic use MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma. This phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma. METHODS: This was a prospective, randomised, open-label, parallel-group, phase 3 study done at 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible. Patients were randomly assigned (3:2) to isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). Patients in the isatuximab group received isatuximab 10 mg/kg intravenously weekly for the first 4 weeks, then every 2 weeks. Both groups received the approved schedule of intravenous carfilzomib and oral or intravenous dexamethasone. Treatment continued until progression or unacceptable toxicity. The primary endpoint was progression-free survival and was assessed in the intention-to-treat population according to assigned treatment. Safety was assessed in all patients who received at least one dose according to treatment received. The study is registered at ClinicalTrials.gov, NCT03275285. FINDINGS: Between Nov 15, 2017, and March 21, 2019, 302 patients with a median of two previous lines of therapy were enrolled. 179 were randomly assigned to the isatuximab group and 123 to the control group. Median progression-free survival was not reached in the isatuximab group compared with 19·15 months (95% CI 15·77-not reached) in the control group, with a hazard ratio of 0·53 (99% CI 0·32-0·89; one-sided p=0·0007). Treatment-emergent adverse events (TEAEs) of grade 3 or worse occurred in 136 (77%) of 177 patients in the isatuximab group versus 82 (67%) of 122 in the control group, serious TEAEs occurred in 105 (59%) versus 70 (57%) patients, and TEAEs led to discontinuation in 15 (8%) versus 17 (14%) patients. Fatal TEAEs during study treatment occurred in six (3%) versus four (3%) patients. INTERPRETATION: The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population. FUNDING: Sanofi. VIDEO ABSTRACT.
Centro Integrado de Hematologia e Oncologia Hospital Mãe de Deus Porto Alegre Brazil
Department of Haematology University College Hospital London UK
Department of Hematology University Hospital Hôtel Dieu Nantes France
Department of Hematology University of California San Francisco San Francisco CA USA
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Department of Internal Medicine Seoul National University Hospital Seoul South Korea
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Sao Paolo Brazil
Lille University Hospital Lille France
Myeloma Amyloidosis Center Japanese Red Cross Medical Center Tokyo Japan
Perth Blood Institute Murdoch University Perth WA Australia
Sanofi R and D Chilly Mazarin France
Sanofi R and D Vitry sur Seine France
Service d'Hématologie et Thérapie Cellulaire CHU and CIC Inserm 1402 Poitiers France
The National and Kapodistrian University of Athens Athens Greece
Translational Genomics Research Institute City of Hope Cancer Center Phoenix AZ USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012396
- 003
- CZ-PrNML
- 005
- 20220506130540.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(21)00592-4 $2 doi
- 035 __
- $a (PubMed)34097854
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Moreau, Philippe $u Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: philippe.moreau@chu-nantes.fr
- 245 10
- $a Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial / $c P. Moreau, MA. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Špička, R. Baker, K. Kim, G. Martinez, CK. Min, L. Pour, X. Leleu, A. Oriol, Y. Koh, K. Suzuki, ML. Risse, G. Asset, S. Macé, T. Martin, IKEMA study group
- 520 9_
- $a BACKGROUND: Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma. This phase 3, open-label study compared the efficacy of isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma. METHODS: This was a prospective, randomised, open-label, parallel-group, phase 3 study done at 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients with relapsed or refractory multiple myeloma aged at least 18 years who had received one to three previous lines of therapy and had measurable serum or urine M-protein were eligible. Patients were randomly assigned (3:2) to isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). Patients in the isatuximab group received isatuximab 10 mg/kg intravenously weekly for the first 4 weeks, then every 2 weeks. Both groups received the approved schedule of intravenous carfilzomib and oral or intravenous dexamethasone. Treatment continued until progression or unacceptable toxicity. The primary endpoint was progression-free survival and was assessed in the intention-to-treat population according to assigned treatment. Safety was assessed in all patients who received at least one dose according to treatment received. The study is registered at ClinicalTrials.gov, NCT03275285. FINDINGS: Between Nov 15, 2017, and March 21, 2019, 302 patients with a median of two previous lines of therapy were enrolled. 179 were randomly assigned to the isatuximab group and 123 to the control group. Median progression-free survival was not reached in the isatuximab group compared with 19·15 months (95% CI 15·77-not reached) in the control group, with a hazard ratio of 0·53 (99% CI 0·32-0·89; one-sided p=0·0007). Treatment-emergent adverse events (TEAEs) of grade 3 or worse occurred in 136 (77%) of 177 patients in the isatuximab group versus 82 (67%) of 122 in the control group, serious TEAEs occurred in 105 (59%) versus 70 (57%) patients, and TEAEs led to discontinuation in 15 (8%) versus 17 (14%) patients. Fatal TEAEs during study treatment occurred in six (3%) versus four (3%) patients. INTERPRETATION: The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population. FUNDING: Sanofi. VIDEO ABSTRACT.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antiflogistika $x terapeutické užití $7 D000893
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a dexamethason $x terapeutické užití $7 D003907
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x terapeutické užití $7 D007155
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $7 D009101
- 650 _2
- $a oligopeptidy $x terapeutické užití $7 D009842
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Dimopoulos, Meletios-Athanasios $u The National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Mikhael, Joseph $u Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA
- 700 1_
- $a Yong, Kwee $u Department of Haematology, University College Hospital, London, UK
- 700 1_
- $a Capra, Marcelo $u Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil
- 700 1_
- $a Facon, Thierry $u Lille University Hospital, Lille, France
- 700 1_
- $a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Špička, Ivan $u 1st Department of Medicine-Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Baker, Ross $u Perth Blood Institute, Murdoch University, Perth, WA, Australia
- 700 1_
- $a Kim, Kihyun $u Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- 700 1_
- $a Martinez, Gracia $u Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paolo, Brazil
- 700 1_
- $a Min, Chang-Ki $u Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul, South Korea
- 700 1_
- $a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Leleu, Xavier $u Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers, France
- 700 1_
- $a Oriol, Albert $u Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain
- 700 1_
- $a Koh, Youngil $u Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
- 700 1_
- $a Suzuki, Kenshi $u Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan
- 700 1_
- $a Risse, Marie-Laure $u Sanofi R&D, Vitry-sur-Seine, France
- 700 1_
- $a Asset, Gaelle $u Sanofi R&D, Chilly-Mazarin, France
- 700 1_
- $a Macé, Sandrine $u Sanofi R&D, Vitry-sur-Seine, France
- 700 1_
- $a Martin, Thomas $u Department of Hematology, University of California San Francisco, San Francisco, CA, USA
- 710 2_
- $a IKEMA study group
- 773 0_
- $w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 397, č. 10292 (2021), s. 2361-2371
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34097854 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130532 $b ABA008
- 999 __
- $a ok $b bmc $g 1789828 $s 1163597
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 397 $c 10292 $d 2361-2371 $e 20210604 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20220425
